Literature DB >> 25882215

Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease.

Nualpun Sirinupong, Zhe Yang1.   

Abstract

Cystic fibrosis (CF) is a deadly genetic disease that affects the lungs and digestive system. A mutation in the CF transmembrane conductance regulator (CFTR) gene is the cause of the disease. How epigenetics contributes to CFTR expression is still poorly understood. Epigenetics is a mechanism that alters gene expression without changing the underlying DNA sequence. Epigenetic mechanisms include DNA methylation and histone modification. Both mechanisms have been implicated in CFTR gene regulation. Here we review epigenetic regulation of CFTR transcription while discussing potential epigenetic targeting strategies including DNA methyltransferase, histone deacetylase, and histone methyltransferase and demethylase inhibition. Because of the reversibility of epigenetics, targeting epigenetic mechanisms has been an attractive therapeutic approach. However, epigenetic targeting of CF disease is still at its infant stage.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25882215     DOI: 10.2174/1389450116666150416114514

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  10 in total

1.  Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.

Authors:  Birgitta Strandvik; Wanda K O Neal; Mohamed A Ali; Ulf Hammar
Journal:  Exp Biol Med (Maywood)       Date:  2018-03

2.  HDAC inhibitors rescue multiple disease-causing CFTR variants.

Authors:  Frédéric Anglès; Darren M Hutt; William E Balch
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

Review 3.  Mucosal Immunity in Cystic Fibrosis.

Authors:  Christine M Bojanowski; Shiping Lu; Jay K Kolls
Journal:  J Immunol       Date:  2021-12-15       Impact factor: 5.426

4.  Long Non-coding RNA BGas Regulates the Cystic Fibrosis Transmembrane Conductance Regulator.

Authors:  Sheena M Saayman; Amanda Ackley; Jon Burdach; Matthew Clemson; Dieter C Gruenert; Kiyoshi Tachikawa; Pad Chivukula; Marc S Weinberg; Kevin V Morris
Journal:  Mol Ther       Date:  2016-05-30       Impact factor: 11.454

Review 5.  Towards Targeting the Aryl Hydrocarbon Receptor in Cystic Fibrosis.

Authors:  Matteo Puccetti; Giuseppe Paolicelli; Vasileios Oikonomou; Antonella De Luca; Giorgia Renga; Monica Borghi; Marilena Pariano; Claudia Stincardini; Lucia Scaringi; Stefano Giovagnoli; Maurizio Ricci; Luigina Romani; Teresa Zelante
Journal:  Mediators Inflamm       Date:  2018-02-18       Impact factor: 4.711

Review 6.  Cystic Fibrosis Lung Disease in the Aging Population.

Authors:  Lisa Künzi; Molly Easter; Meghan June Hirsch; Stefanie Krick
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

Review 7.  Chasing a Breath of Fresh Air in Cystic Fibrosis (CF): Therapeutic Potential of Selective HDAC6 Inhibitors to Tackle Multiple Pathways in CF Pathophysiology.

Authors:  Simona Barone; Emilia Cassese; Antonella Ilenia Alfano; Margherita Brindisi; Vincenzo Summa
Journal:  J Med Chem       Date:  2022-02-11       Impact factor: 7.446

Review 8.  Role of Histone Post-Translational Modifications in Inflammatory Diseases.

Authors:  Yingying Lin; Ting Qiu; Guifeng Wei; Yueyue Que; Wenxin Wang; Yichao Kong; Tian Xie; Xiabin Chen
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

9.  Downregulation of epithelial sodium channel (ENaC) activity in cystic fibrosis cells by epigenetic targeting.

Authors:  Giovanna Blaconà; Roberto Raso; Stefano Castellani; Silvia Pierandrei; Paola Del Porto; Giampiero Ferraguti; Fiorentina Ascenzioni; Massimo Conese; Marco Lucarelli
Journal:  Cell Mol Life Sci       Date:  2022-04-25       Impact factor: 9.207

Review 10.  Research advances in molecular mechanisms underlying the pathogenesis of cystic fibrosis: From technical improvement to clinical applications (Review).

Authors:  Tao Wei; Hongshu Sui; Yanping Su; Wanjing Cheng; Yunhua Liu; Zilin He; Qingchao Ji; Changlong Xu
Journal:  Mol Med Rep       Date:  2020-10-16       Impact factor: 2.952

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.